[Skip to Content]
[Skip to Content Landing]
August 16, 1965

Evaluation of Phosphorus 32 for Intractable Pain Secondary to Prostatic Carcinoma Metastases

Author Affiliations

From the Division of Urology (Drs. Joshi, Seery, and Goldberg) and the Department of Radiation Medicine (Dr. Goldman), the Long Island Jewish Hospital and Queens Hospital Center Affiliation, Jamaica, NY.

JAMA. 1965;193(7):621-623. doi:10.1001/jama.1965.03090070071032

PHYSICIANS are often faced with the serious problem of intractable pain in patients with metastatic carcinoma of the prostate. The hormonal treatment, either by orchiectomy or external estrogens, is the most widely used therapy for inoperable carcinoma of the prostate since the discovery of endocrine influence on prostatic cancer by Huggins1 in 1941. However, some patients, after a period of symptomatic relief, fail to respond to the conservative therapy of castration and estrogens used alone or in combination. External radiation, bilateral adrenalectomy, hypophysectomy, and chordotomy have been used to relieve the incapacitating pain. The studies made by Lawrence and Tobins,2 who used radioactive phosphorus on neoplastic tissues, stimulated interest in this method of therapy as a possible means of improving palliation in advanced malignancy. In recent years,32P has received increased recognition for palliation in these cases, particularly where bony metastases are present.3-5 In this series,